Tag

en US- Pagina 179

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial – World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

mercoledì, 22 Luglio 2026
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai,

Citadel Securities Opens Amsterdam Office

mercoledì, 22 Luglio 2026
Next-Generation Global Market Maker Expands European Presence to Better Serve Institutional Clients, European Capital Markets   MIAMI, July 22, 2026 /PRNewswire/ — Citadel Securities, a technology-driven, next-generation global market maker, today announced